The Impact of Diet on AD Biomarkers in a Community‐Based Sample.

Background: Greater adherence to the Mediterranean Diet (MeDi) is associated with lower risk for cardiovascular disease, slower cognitive decline, and reduced risk for Alzheimer’s Disease (AD). However, its association with AD biomarkers is not well known. We hypothesized that greater MeDi adherence is associated with reduced amyloid and tau PET burden in a community‐based sample of older adults in Northern Manhattan.

Differential association of moderate alcohol use with neurodegeneration, cerebrovascular disease, and cognition by racial, ethnic and sex/gender groups in middle age.

Background: Moderate alcohol use may be associated with brain and cognitive benefits compared to heavy alcohol use. However, results have varied. We hypothesized that the relationship between alcohol use and cognition is mediated by neurodegenerative and cerebrovascular measures in a diverse middle‐aged sample of non‐alcohol dependent community‐dwelling adults in Northern Manhattan.

Microglia density measured by TSPO PET across amyloid positivity and clinical variants.

Background: We hypothesized that TSPO PET, which measures microglia density, would be elevated in the presence of amyloid and impairment across different clinical variants in a pattern that follows their characteristic tau distribution.

Method: Participants (n = 17 amyloid‐negative control, 3 amyloid‐positive AD, 2 amyloid‐positive PCA, 6 amyloid‐negative with impairment (1 aMCI, 1 MCI, 3 AD, 1 LATE); age = 69±7, 43% women) from the Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer’s Disease study underwent amyloid PET (Florbetaben), tau PET (MK6240), and TSPO PET (ER176). Amyloid positivity was determined by visual read.

The Impact of Diet on AD Biomarkers in a Community‐Based Sample.

Background: Greater adherence to the Mediterranean Diet (MeDi) is associated with lower risk for cardiovascular disease, slower cognitive decline, and reduced risk for Alzheimer’s Disease (AD). However, its association with AD biomarkers is not well known. We hypothesized that greater MeDi adherence is associated with reduced amyloid and tau PET burden in a community‐based sample of older adults in Northern Manhattan.

Differential association of moderate alcohol use with neurodegeneration, cerebrovascular disease, and cognition by racial, ethnic and sex/gender groups in middle age.

Background: Moderate alcohol use may be associated with brain and cognitive benefits compared to heavy alcohol use. However, results have varied. We hypothesized that the relationship between alcohol use and cognition is mediated by neurodegenerative and cerebrovascular measures in a diverse middle‐aged sample of non‐alcohol dependent community‐dwelling adults in Northern Manhattan.

Clinical researchers' insights on key data for eligibility screening in clinical studies.

Introduction: Clinical research is critical for healthcare advancement, but participant recruitment remains challenging. Clinical research professionals (CRPs; e.g.

Microglia measured by TSPO PET are associated with Alzheimer's disease pathology and mediate key steps in a disease progression model.

Introduction: Evidence suggests microglial activation precedes regional tau and neurodegeneration in Alzheimer's disease (AD). We characterized microglia with translocator protein (TSPO) positron emission tomography (PET) within an AD progression model where global amyloid beta (Aβ) precedes local tau and neurodegeneration, resulting in cognitive impairment.

Methods: Florbetaben, PBR28, and MK-6240 PET, T1 magnetic resonance imaging, and cognitive measures were performed in 19 cognitively unimpaired older adults and 22 patients with mild cognitive impairment or mild AD to examine associations among microglia activation, Aβ, tau, and cognition, adjusting for neurodegeneration.

Psychotic symptoms are associated with elevated tau PET signal in the amygdala independent of Alzheimer's disease clinical severity and amyloid burden.

Background: Psychosis in Alzheimer's disease (AD) is associated with worse outcomes, yet no established biomarkers exist for early diagnosis and intervention. We compared tau PET burden across older individuals with and without psychotic symptoms.

Methods: [F]AV1451 tau PET binding was compared between 26 Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects with psychotic symptoms (delusions and/or hallucinations) and 26 ADNI subjects without psychotic symptoms, matched for age, sex, race/ethnicity, and clinical severity.